168 related articles for article (PubMed ID: 20055660)
81. Lenalidomide as first-line therapy for elderly CLL patients.
Gilbert JA
Lancet Oncol; 2013 Aug; 14(9):e345. PubMed ID: 24058966
[No Abstract] [Full Text] [Related]
82. New agents in chronic lymphocytic leukemia.
Lin TS
Curr Hematol Malig Rep; 2010 Jan; 5(1):29-34. PubMed ID: 20425394
[TBL] [Abstract][Full Text] [Related]
83. Maintenance therapy for B-chronic lymphocytic leukemia.
O'Brien S; Kay NE
Clin Adv Hematol Oncol; 2011 Jan; 9(1):22-31. PubMed ID: 21326143
[TBL] [Abstract][Full Text] [Related]
84. Externally validated predictive clinical model for untreated del(17p13.1) chronic lymphocytic leukemia patients.
Stephens DM; Ruppert AS; Weirda WG; Jones JA; Woyach JA; Maddocks K; Jaglowski SM; Andritsos LA; Flynn JM; Grever MR; Lozanski G; Tam C; O'Brien S; Keating MJ; Muthusamy N; Abruzzo LV; Heerema NA; Byrd JC
Am J Hematol; 2015 Nov; 90(11):967-9. PubMed ID: 26202978
[TBL] [Abstract][Full Text] [Related]
85. Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer.
Ramsay AG; Clear AJ; Fatah R; Gribben JG
Blood; 2012 Aug; 120(7):1412-21. PubMed ID: 22547582
[TBL] [Abstract][Full Text] [Related]
86. Role for CCG-trinucleotide repeats in the pathogenesis of chronic lymphocytic leukemia.
Auer RL; Jones C; Mullenbach RA; Syndercombe-Court D; Milligan DW; Fegan CD; Cotter FE
Blood; 2001 Jan; 97(2):509-15. PubMed ID: 11154230
[TBL] [Abstract][Full Text] [Related]
87. Impact of targeted therapy on outcome of chronic lymphocytic leukemia patients with relapsed del(17p13.1) karyotype at a single center.
Stephens DM; Ruppert AS; Jones JA; Woyach J; Maddocks K; Jaglowski SM; Andritsos LA; Flynn JM; Grever MR; Lozanski G; Johnson AJ; Muthusamy N; Heerema NA; Byrd JC
Leukemia; 2014 Jun; 28(6):1365-8. PubMed ID: 24451411
[No Abstract] [Full Text] [Related]
88. Overexpression of Galectin-3 in Chronic Lymphocytic Leukemia Is Associated With 17p Deletion: A Short Report.
Michalová Z; Čoma M; Kičová M; Gabzdilová J; Dedinská K; Guman T; Hájiková M; Veselinyová D; Giertlova M; Gál P; Šarišský M
Anticancer Res; 2019 Jun; 39(6):2805-2810. PubMed ID: 31177117
[TBL] [Abstract][Full Text] [Related]
89. Inflammation, TNFα and endothelial dysfunction link lenalidomide to venous thrombosis in chronic lymphocytic leukemia.
Aue G; Nelson Lozier J; Tian X; Cullinane AM; Soto S; Samsel L; McCoy P; Wiestner A
Am J Hematol; 2011 Oct; 86(10):835-40. PubMed ID: 21812019
[TBL] [Abstract][Full Text] [Related]
90. An Anecdotal Case Report of Chronic Lymphatic Leukemia with del(11q) Treated with Ibrutinib: Artificial Nourishment and Physical Activity Program.
Sica A; Sagnelli C; Papa A; Ciccozzi M; Sagnelli E; Calogero A; Martinelli E; Casale B
Int J Environ Res Public Health; 2020 Mar; 17(6):. PubMed ID: 32188040
[TBL] [Abstract][Full Text] [Related]
91. Activation of Th1 Immunity within the Tumor Microenvironment Is Associated with Clinical Response to Lenalidomide in Chronic Lymphocytic Leukemia.
Aue G; Sun C; Liu D; Park JH; Pittaluga S; Tian X; Lee E; Soto S; Valdez J; Maric I; Stetler-Stevenson M; Yuan C; Nakamura Y; Muranski P; Wiestner A
J Immunol; 2018 Oct; 201(7):1967-1974. PubMed ID: 30104242
[TBL] [Abstract][Full Text] [Related]
92. How does lenalidomide target the chronic lymphocytic leukemia microenvironment?
Kater AP; Tonino SH; Egle A; Ramsay AG
Blood; 2014 Oct; 124(14):2184-9. PubMed ID: 25161268
[TBL] [Abstract][Full Text] [Related]
93. Randomized controlled trial of individualized, low dose, fixed duration lenalidomide maintenance versus observation after frontline chemo-immunotherapy in CLL.
Jindal N; Lad DP; Malhotra P; Prakash G; Khadwal A; Jain A; Sachdeva MS; Sreedharanunni S; Naseem S; Varma N; Varma S
Leuk Lymphoma; 2021 Jul; 62(7):1674-1681. PubMed ID: 33612059
[TBL] [Abstract][Full Text] [Related]
94. Lenalidomide differently modulates CD20 antigen surface expression on chronic lymphocytic leukemia B-cells.
D'Arena G; Ruggieri V; D'Auria F; La Rocca F; Simeon V; Statuto T; Caivano A; Telesca D; Del Vecchio L; Musto P
Leuk Lymphoma; 2015; 56(8):2458-9. PubMed ID: 25547653
[No Abstract] [Full Text] [Related]
95. c-myc and K-ras-2 oncogenes in B-cell chronic lymphocytic leukemia with del(12)(p13).
Wang TY; Samples DM; Dabdoub R; Prakash O
Cancer Genet Cytogenet; 1991 Jan; 51(1):125-30. PubMed ID: 1984840
[TBL] [Abstract][Full Text] [Related]
96. Sustained long-lasting responses after lenalidomide discontinuation in patients with chronic lymphocytic leukemia.
Strati P; Ferrajoli A; Wierda WG; Jain N; Thompson PA; O'Brien SM; Rezvani K; Kantarjian HM; Burger JA; Hinojosa CO; Keating MJ; Estrov Z
Leukemia; 2018 Oct; 32(10):2278-2281. PubMed ID: 29479067
[No Abstract] [Full Text] [Related]
97. Immunotherapeutic approaches have the potential to brighten the future not only for patients with del(17p13.1), but for all CLL patients.
McClanahan F; Gribben JG
Oncology (Williston Park); 2012 Nov; 26(11):1055, 1058. PubMed ID: 23330345
[No Abstract] [Full Text] [Related]
98. T cells in CLL: lost in migration.
Ysebaert L
Blood; 2013 Apr; 121(14):2580-2. PubMed ID: 23557968
[No Abstract] [Full Text] [Related]
99. Chronic lymphocytic leukemia with deletion 17p: emerging treatment options.
Jain N; O'Brien S
Oncology (Williston Park); 2012 Nov; 26(11):1067, 1070. PubMed ID: 23330347
[No Abstract] [Full Text] [Related]
100. DNA-PK hyperactivation occurs in deletion 11q chronic lymphocytic leukemia and is both a biomarker and therapeutic target for drug-resistant disease.
Kost SEF; Saleh A; Yuan SH; Kuzio B; Gibson SB; Yang L; Banerji V; Johnston JB; Katyal S
Blood Cancer J; 2023 Jan; 13(1):20. PubMed ID: 36707503
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
